Bronchiectasis and low dose erythromyci

Not Applicable

Completed

• Conditions: on-Cystic Fibrosis Bronchiectasis; Non-Cystic Fibrosis Bronchiectasis; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12608000460303
• Lead Sponsor: Dr David Serisier

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-09-16
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 118

Inclusion Criteria

1. Bronchiectasis on high-resolution computed tomographic scans of the lungs
2. At least 2 pulmonary exacerbations in the preceding 12 months requiring antibiotic therapy
3. Chronic productive cough with daily sputum production
4. Clinically stable and no alteration to therapies in the 4 weeks preceding screening

Exclusion Criteria

1. Cystic Fibrosis, tuberrculosis, non-tuberculous mycobacterial infection, focal endobronchial obstructing lesion
2. Smoking within the preceding 6 months
3. Maintenance oral antibiotic therapy
4. Any condition likely to result in a shortened life span within the 12 months of the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mean rate of protocol-defined pulmonary exacerbations per patient per year, measured by intention to treat[Measured at all visits (monthly), but outcome measure is evaluated at 48 weeks after randomisation];Mean rate of protocol-defined pulmonary exacerbations per patient per year, measured per protocol (ie subjects who do not complete 48 weeks of therapy for whatever reason will be excluded from this analysis)[Measured at all visits (monthly), but outcome measure is evaluated at 48 weeks after randomisation]